MicroRNA-526a targets p21-activated kinase 7 to inhibit tumorigenesis in hepatocellular carcinoma Retraction in /10.3892/mmr.2023.13007

Zhan,Lei; Pan,Yaozhen; Chen,Ling; Chen,Zili; Zhang,Hong; Sun,Chengyi

doi:10.3892/mmr.2017.6658

MicroRNA-526a targets p21-activated kinase 7 to inhibit tumorigenesis in hepatocellular carcinoma

Retraction in: /10.3892/mmr.2023.13007

Authors:
- Lei Zhan
- Yaozhen Pan
- Ling Chen
- Zili Chen
- Hong Zhang
- Chengyi Sun
View Affiliations

Affiliations: Department of Biliary‑Hepatic Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550001, P.R. China
Published online on: May 31, 2017 https://doi.org/10.3892/mmr.2017.6658
Pages: 837-844

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs belong to a series of noncoding RNAs and have diverse roles in several biological processes. The association between aberrant microRNA expression and tumorigenesis is complex and remains to be fully elucidated. The present study investigated whether microRNA (miR) ‑526a can suppress the progression of hepatocellular carcinoma (HCC) in vitro and in vivo. Reverse transcription‑quantitative polymerase chain reaction, luciferase reporter assay, invasion assay, western blotting and in vivo implantation were used to investigate the potential function of miR‑526a. The present study observed that the level of miR‑526a was downregulated in HCC tissues and well‑established cell lines. In addition, the ectopic introduction of miR‑526a into Huh7 and HepG2 cells significantly attenuated HCC tumorigenesis, including proliferation, migration and invasion. The growth of tumor xenografts was also inhibited following transfection with miR‑526a. Using overlapping strategies, p21‑activated kinase 7 (PAK7) was predicted to be a target for miR‑526a, and this was verified experimentally. An inverse correlation was found between miR‑526a and PAK7 in HCC tissues. The results of the present study revealed a novel function of miR‑526a and may provide crucial insight into therapeutic interventions targeting microRNAs.

View Figures

View References

1	Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS and Sherman M: Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. Liver Int. 35:2155–2166. 2015. View Article : Google Scholar : PubMed/NCBI
2	Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, et al: MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 140:1618–1628.e16. 2011. View Article : Google Scholar : PubMed/NCBI
3	Huang G, Lau WY, Wang ZG, Pan ZY, Yuan SX, Shen F, Zhou WP and Wu MC: Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: A randomized controlled trial. Ann Surg. 261:56–66. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B and Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: Recent advancements. Semin Liver Dis. 30:35–51. 2010. View Article : Google Scholar : PubMed/NCBI
5	Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol. 52:550–559. 2010. View Article : Google Scholar : PubMed/NCBI
6	Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 135:1972–1983, e1-e11. 2008. View Article : Google Scholar : PubMed/NCBI
7	Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
8	Cai Y, Yu X, Hu S and Yu J: A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics. 7:147–154. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wang YQ, Ren YF, Song YJ, Xue YF, Zhang XJ, Cao ST, Deng ZJ, Wu J, Chen L, Li G, et al: MicroRNA-581 promotes hepatitis B virus surface antigen expression by targeting Dicer and EDEM1. Carcinogenesis. 35:2127–2133. 2014. View Article : Google Scholar : PubMed/NCBI
10	Su X, Wang H, Ge W, Yang M, Hou J, Chen T, Li N and Cao X: An in vivo method to identify microRNA targets not predicted by computation algorithms: p21 targeting by miR-92a in cancer. Cancer Res. 75:2875–2885. 2015. View Article : Google Scholar : PubMed/NCBI
11	Shih YT, Wang MC, Zhou J, Peng HH, Lee DY and Chiu JJ: Endothelial progenitors promote hepatocarcinoma intrahepatic metastasis through monocyte chemotactic protein-1 induction of microRNA-21. Gut. 64:1132–1147. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cui W, Huang Z, He H, Gu N, Qin G, Lv J, Zheng T, Sugimoto K and Wu Q: MiR-1188 at the imprinted Dlk1-Dio3 domain acts as a tumor suppressor in hepatoma cells. Mol Biol Cell. 26:1416–1427. 2015. View Article : Google Scholar : PubMed/NCBI
13	Liu Q, Xu Y, Wei S, Gao W, Chen L, Zhou T, Wang Z, Ying M and Zheng Q: miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1. Biosci Rep. 35:e002292015. View Article : Google Scholar : PubMed/NCBI
14	Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar : PubMed/NCBI
15	Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z and Zheng X: miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer. 10:3542010. View Article : Google Scholar : PubMed/NCBI
16	Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH and Zhuang SM: Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 51:836–845. 2010.PubMed/NCBI
17	Coulouarn C, Factor VM, Andersen JB, Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. 28:3526–3536. 2009. View Article : Google Scholar : PubMed/NCBI
18	Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, et al: Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 41:843–848. 2009. View Article : Google Scholar : PubMed/NCBI
19	Chung JY and Hewitt SM: An optimized RNA extraction method from archival formalin-fixed paraffin-embedded tissue. Methods Mol Biol. 611:19–27. 2010. View Article : Google Scholar : PubMed/NCBI
20	Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
21	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:(Database Issue). D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, et al: Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol. 16:182015. View Article : Google Scholar : PubMed/NCBI
23	Yang Y, Xing Y, Liang C, Hu L, Xu F and Chen Y: Crucial microRNAs and genes of human primary breast cancer explored by microRNA-mRNA integrated analysis. Tumour Biol. 36:5571–5579. 2015. View Article : Google Scholar : PubMed/NCBI
24	Hata A and Kashima R: Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 51:121–134. 2016. View Article : Google Scholar : PubMed/NCBI
25	Leonardo TR, Schultheisz HL, Loring JF and Laurent LC: The functions of microRNAs in pluripotency and reprogramming. Nat Cell Biol. 14:1114–1121. 2012. View Article : Google Scholar : PubMed/NCBI
26	Di Leva G, Garofalo M and Croce CM: MicroRNAs in cancer. Annu Rev Pathol. 9:287–314. 2014. View Article : Google Scholar : PubMed/NCBI
27	Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, et al: Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 123:4449–4463. 2013. View Article : Google Scholar : PubMed/NCBI
28	Melzer J, Kraft KF, Urbach R and Raabe T: The p21-activated kinase Mbt is a component of the apical protein complex in central brain neuroblasts and controls cell proliferation. Development. 140:1871–1881. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gu J, Li K, Li M, Wu X, Zhang L, Ding Q, Wu W, Yang J, Mu J, Wen H, et al: A role for p21-activated kinase 7 in the development of gastric cancer. FEBS J. 280:46–55. 2013. View Article : Google Scholar : PubMed/NCBI
30	Zhang HH, Zhang ZY, Che CL, Mei YF and Shi YZ: Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines. Int J Clin Exp Pathol. 6:1734–1746. 2013.PubMed/NCBI
31	Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA and Zhuang H: Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer. 118:2431–2442. 2012. View Article : Google Scholar : PubMed/NCBI
32	Giroux V, Dagorn JC and Iovanna JL: A review of kinases implicated in pancreatic cancer. Pancreatology. 9:738–754. 2009. View Article : Google Scholar : PubMed/NCBI
33	Han K, Zhou Y, Gan ZH, Qi WX, Zhang JJ, Fen T, Meng W, Jiang L, Shen Z and Min DL: p21-activated kinase 7 is an oncogene in human osteosarcoma. Cell Biol Int. 38:1394–1402. 2014. View Article : Google Scholar : PubMed/NCBI
34	Wells CM and Jones GE: The emerging importance of group II PAKs. Biochem J. 425:465–473. 2010. View Article : Google Scholar : PubMed/NCBI
35	Tang YW: Transcriptomic approach predicts tempo of disease progression in HIV-1 infections. Clin Chem. 59:1143–1144. 2013. View Article : Google Scholar : PubMed/NCBI
36	Xu C, He X, Zheng Z, Zhang Z, Wei C, Guan K, Hou L, Zhang B, Zhu L, Cao Y, et al: Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response. J Virol. 88:11356–11368. 2014. View Article : Google Scholar : PubMed/NCBI
37	Fu Y, Yi Z, Wu X, Li J and Xu F: Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol. 49:4246–4251. 2011. View Article : Google Scholar : PubMed/NCBI
38	Zhang ZY, Fu SL, Xu SQ, et al: By downregulating Ku80, hsa-miR-526b suppresses non-small cell lung cancer. Oncotarget. 6:1462–1477. 2015. View Article : Google Scholar : PubMed/NCBI